Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408225 · ClinicalTrials.gov registry record
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
A clinical trial of Multiple Myeloma and AL Amyloidosis, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT01408225 is a study of Multiple Myeloma and AL Amyloidosis that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 5,000 participants, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01408225, a study of Multiple Myeloma and AL Amyloidosis, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
Conditions Studied
Interventions
- PROCEDURE tissue banking
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2011-03-17 |
| Est. Completion | 2050-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408225
The ClinicalTrials.gov registry entry for NCT01408225 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which tissue banking is the first listed.
NCT01408225 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01408225 about?
NCT01408225 is a clinical study titled "Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource". The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance:...
What is the current status of trial NCT01408225?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2011-03-17. Estimated completion is 2050-03.
What conditions does trial NCT01408225 study?
This clinical trial studies the following conditions: Multiple Myeloma, AL Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Dyscrasias.
What interventions are being tested in trial NCT01408225?
The interventions under investigation include: tissue banking (PROCEDURE).
Who is sponsoring clinical trial NCT01408225?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408225 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.